Omega-3 Fatty Acids: EPA, DHA, and What the Clinical Evidence Actually Shows
A comprehensive evidence review of omega-3 supplementation covering EPA vs DHA ratios, cardiovascular outcomes, brain health data, optimal dosing from clinical trials, and which forms actually absorb.
Lead Science Writer · Peer-Reviewed Sources
Omega-3 fatty acids are among the most studied nutrients in clinical research, with over 30,000 published papers. Yet the supplement aisle presents a confusing array of options — fish oil, krill oil, algal oil, varying EPA:DHA ratios — with marketing claims that often outpace the evidence.
This guide cuts through the noise by examining what large-scale clinical trials, systematic reviews, and meta-analyses actually demonstrate about omega-3 supplementation.
The Biology: Why Omega-3s Matter
Omega-3 fatty acids are polyunsaturated fats that serve as structural components of cell membranes throughout the body. The two most biologically active forms are:
- EPA (eicosapentaenoic acid): Primarily anti-inflammatory. Competes with arachidonic acid in the cyclooxygenase and lipoxygenase pathways, reducing pro-inflammatory eicosanoid production.
- DHA (docosahexaenoic acid): Concentrated in neural tissue. Comprises approximately 40% of polyunsaturated fatty acids in the brain and 60% in the retina.
The plant-derived omega-3, ALA (alpha-linolenic acid), converts to EPA and DHA at extremely low rates — approximately 5-8% to EPA and less than 0.5% to DHA in most studies. This makes direct EPA/DHA supplementation far more efficient.
Cardiovascular Evidence
The Landmark Trials
REDUCE-IT (2019) — 8,179 patients on statins with elevated triglycerides received 4g/day icosapent ethyl (pure EPA) or placebo. Results: 25% relative risk reduction in major cardiovascular events (HR 0.75, 95% CI 0.68-0.83). This is one of the strongest supplement RCT results in cardiology.
STRENGTH (2020) — 13,078 patients received 4g/day EPA+DHA combination. Results: No significant reduction in cardiovascular events (HR 0.99). The contrast with REDUCE-IT sparked ongoing debate about EPA-only vs. EPA+DHA formulations.
VITAL (2019) — 25,871 healthy adults received 1g/day omega-3 or placebo for 5.3 years. Results: No significant reduction in major cardiovascular events overall, but a 28% reduction in heart attack risk (HR 0.72).
The evidence suggests high-dose EPA (4g/day) provides meaningful cardiovascular protection in high-risk populations. Standard-dose fish oil (1-2g/day) shows more modest effects.
Brain Health and Cognition
DHA is essential for brain development and maintenance, but supplementation evidence in healthy adults is mixed:
- Prevention of cognitive decline: A 2022 Cochrane review of 25,000+ participants found no clear benefit of omega-3 supplementation for preventing dementia in cognitively healthy older adults.
- Depression: A 2019 meta-analysis in Translational Psychiatry (26 RCTs, n=2,160) found EPA-predominant formulations showed significant benefit for major depressive disorder (SMD = -0.61), while DHA-predominant did not.
- ADHD: A 2018 meta-analysis found modest benefits for ADHD symptoms in children, particularly with higher EPA doses.
The pattern: EPA appears more relevant for mood disorders, while DHA is structural and important during development.
Dosing: What the Evidence Supports
| Goal | Dose | EPA:DHA Ratio | Evidence Level |
|---|---|---|---|
| General health | 1-2g combined EPA+DHA/day | Balanced | Moderate |
| Cardiovascular (high-risk) | 4g EPA/day | EPA-only | Strong (REDUCE-IT) |
| Depression (adjunct) | 1-2g EPA/day | EPA-predominant (>60%) | Moderate |
| Triglyceride reduction | 2-4g EPA+DHA/day | Either | Strong |
| Pregnancy/development | 200-300mg DHA/day minimum | DHA-predominant | Strong |
Important: Doses above 3g/day may increase bleeding risk and should be discussed with a physician.
Form and Absorption
- Triglyceride (TG) form: Natural form found in fish. Absorption rate approximately 50% higher than ethyl ester form.
- Ethyl ester (EE) form: Most common in supplements. Less expensive but lower bioavailability, especially without fat.
- Phospholipid form: Found in krill oil. May offer superior brain bioavailability but clinical outcome data is limited.
Practical takeaway: If using ethyl ester fish oil, always take with a fat-containing meal — absorption increases 3-fold compared to fasting.
Oxidation and Quality
A 2015 analysis found that 50% of over-the-counter fish oil products exceeded recommended oxidation levels. Look for TOTOX value below 26, third-party testing (IFOS, ConsumerLab, NSF), opaque packaging, and no strong fishy smell.
Safety and Interactions
- Blood thinning: High doses (>3g/day) may potentiate anticoagulant effects
- Surgery: Consider stopping high-dose fish oil 1-2 weeks before surgery
- GI effects: Fishy burps and GI discomfort are common; enteric-coated capsules help
The Bottom Line
Omega-3 supplementation has a strong evidence base, but the details matter. High-dose pure EPA has the strongest cardiovascular evidence. For depression, EPA-predominant formulations outperform DHA-predominant ones. Quality and form significantly affect absorption. For most people, 1-2g combined EPA+DHA daily from a quality triglyceride-form supplement, taken with food, represents a reasonable evidence-based approach.